Romilkimab showed significant effects on skin changes in patients with systemic sclerosis, according to phase 2 trial results published in the Annals of the Rheumatic Diseases.

In this double-blind, proof-of-concept, phase 2 study, 97 patients aged ≥18 years with diffuse cutaneous SSc (dcSSc) were randomized to receive romilkimab (n = 48) or placebo (n = 49) for 24 weeks. Change in modified Rodnan skin…

View Conference Coverage

Take a look at some of our conference coverage, visit our roundup section.

Conference Roundup

  1. Jun 15, 2020

Study: Breakthrough drug significantly delays the onset of type 1 diabetes

Teplizumab significantly delayed the onset of type 1 diabetes (T1D) by 3 years compared to placebo, according to data presented at the American Diabetes Association (ADA)'s 80th Scientific Sessions.

In the…

Journal Scan